This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday – Aclaris Therapeutics (NASDAQ:ACRS), Alkermes (NASDAQ:ALKS)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Needham analyst Ami Fadia initiated coverage on Alkermes plc ALKS with a Buy rating and announced a price target of $45. Alkermes shares closed at $29.90 on Tuesday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Yi Chen initiated coverage on NeuroPace, Inc. NPCE with a Buy rating and announced a price target of $18. NeuroPace shares closed at $12.66 on Tuesday. See how other analysts view this stock.
• Wedbush analyst Martin Fan initiated coverage on Aclaris Therapeutics, Inc. ACRS with an Outperform rating and announced a price target of $8. Aclaris Therapeutics shares closed at $1.27 on Tuesday. See how other analysts view this stock.
• Redburn Atlantic analyst Mike Harrison initiated coverage on Marvell Technology, Inc. MRVL with a Neutral rating and announced a price target of $67. Marvell Tech shares closed at $63.82 on Tuesday. See how other analysts view this stock.
• Redburn Atlantic analyst Mike Harrison initiated coverage on Arista Networks Inc ANET with a Buy rating and announced a price target of $112. Arista Networks shares closed at $92.49 on Tuesday. See how other analysts view this stock.

Considering buying ANET stock? Here’s what analysts think:

Read This Next:

• Jim Cramer Says Rocket Is A ‘Very Fine’ Company, Recommends Buying This Health Care Stock

Photo via Shutterstock